“…According to our study, although several parameters were associated with shorter disease-free and disease-specific survivals, few remained independently significant by multivariate analysis: the presence of an extracapsular invasion for diseasefree survival and both the maximum diameter of the largest metastasis and the presence of an ulceration of the primary melanoma for disease-specific survival. These results are concordant with the conclusions of Ranieri et al 13 and Cochran et al 14 that the tumour burden was predictive of survival. However, Ranieri et al 13 found that ulceration had no impact on the prognosis.…”
Section: Discussionsupporting
confidence: 92%
“…These results are concordant with the conclusions of Ranieri et al 13 and Cochran et al 14 that the tumour burden was predictive of survival. However, Ranieri et al 13 found that ulceration had no impact on the prognosis. Our study is the first to point out such a correlation.…”
Section: Discussionsupporting
confidence: 92%
“…Ranieri et al 13 drew the conclusion that the maximum diameter of the largest SLN tumour deposit was associated with outcome: the cut-off point of 3 mm appeared to be particularly relevant with regard to 5-year disease-free and overall survival by multivariate analysis.…”
Our study confirms the previously demonstrated strong prognostic value of SLNB. It also confirms the relationship between tumour burden in the SLN (evaluated by the maximum diameter of the largest metastasis) and clinical outcome. We point out a new micromorphometric feature of SLN, which seems to be predictive of CLND status: the lowest diameter of the largest metastasis.
“…According to our study, although several parameters were associated with shorter disease-free and disease-specific survivals, few remained independently significant by multivariate analysis: the presence of an extracapsular invasion for diseasefree survival and both the maximum diameter of the largest metastasis and the presence of an ulceration of the primary melanoma for disease-specific survival. These results are concordant with the conclusions of Ranieri et al 13 and Cochran et al 14 that the tumour burden was predictive of survival. However, Ranieri et al 13 found that ulceration had no impact on the prognosis.…”
Section: Discussionsupporting
confidence: 92%
“…These results are concordant with the conclusions of Ranieri et al 13 and Cochran et al 14 that the tumour burden was predictive of survival. However, Ranieri et al 13 found that ulceration had no impact on the prognosis. Our study is the first to point out such a correlation.…”
Section: Discussionsupporting
confidence: 92%
“…Ranieri et al 13 drew the conclusion that the maximum diameter of the largest SLN tumour deposit was associated with outcome: the cut-off point of 3 mm appeared to be particularly relevant with regard to 5-year disease-free and overall survival by multivariate analysis.…”
Our study confirms the previously demonstrated strong prognostic value of SLNB. It also confirms the relationship between tumour burden in the SLN (evaluated by the maximum diameter of the largest metastasis) and clinical outcome. We point out a new micromorphometric feature of SLN, which seems to be predictive of CLND status: the lowest diameter of the largest metastasis.
“…There could be an increased rate of false negative SLN results or a decreased sensitivity in detection of SLN in older patients, although the low level of locoregional recurrence in nodal basins previously determined to be SLN negative seems to suggest an alternative explanation. Perhaps there is an increased rate of hematogenous spread in older patients or a greater tumor burden per positive SLN [7,[17][18][19]. We have observed no differences in IHC-only detected SLN metastases between the two age groups.…”
“…There is significant and growing evidence that microscopic tumor burden in the SLN is prognostically important. [78][79][80][81][82][83][84][85][86][87][88][89][90] SLN tumor burden can be assessed by a variety of micromorphometric parameters, including the maximum size of the largest metastasis, the maximum subcapsular depth (also known as tumor penetrative depth 88 of the deposits and measured from the inner surface of the lymph node capsule to the deepest intranodal tumor cell), the microanatomic location of SLN tumor deposits, the percentage crosssectional area of the SLN that is involved, and the presence of extranodal extension. In various studies, one or more of these parameters has predicted survival in SLN-positive patients.…”
To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria. Key changes in the eighth edition AJCC Cancer Staging Manual include: 1) tumor thickness measurements to be recorded to the nearest 0.1 mm, not 0.01 mm; 2) definitions of T1a and T1b are revised (T1a, <0.8 mm without ulceration; T1b, 0.8–1.0 mm with or without ulceration or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 3) pathological (but not clinical) stage IA is revised to include T1b N0 M0 (formerly pathologic stage IB); 4) the N category descriptors “microscopic” and “macroscopic” for regional node metastasis are redefined as “clinically occult” and “clinically apparent”; 5) prognostic stage III groupings are based on N category criteria and T category criteria (ie, primary tumor thickness and ulceration) and increased from 3 to 4 subgroups (stages IIIA–IIID); 6) definitions of N subcategories are revised, with the presence of microsatellites, satellites, or in-transit metastases now categorized as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes, if any; 7) descriptors are added to each M1 subcategory designation for lactate dehydrogenase (LDH) level (LDH elevation no longer upstages to M1c); and 8) a new M1d designation is added for central nervous system metastases. This evidence-based revision of the AJCC melanoma staging system will guide patient treatment, provide better prognostic estimates, and refine stratification of patients entering clinical trials.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.